



D1F49



BRAWN BIOTECH LTD.

12th February, 2025

The General Manager
The Department of Corporate Services,
BSE Limited, 25th Floor,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai -400001

BSE Scrip Code: 530207
Scrip ID: BRAWN

Sub: Outcome of the Board Meeting of the Company held on 12th February, 2025, and submissions of Un-Audited Financial Results for the Quarter 31.12.2024.

Ref: Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (SEBI Listing regulations).

Dear Sir/Ma'am,

With reference to the captioned subject and pursuant to the provisions of Regulation 30 and Regulation 33 of SEBI Listing Regulations, this is to inform you that the Board of Directors of the Company in its meeting held today, 12th February 2025 has considered and approved the Un-Audited Financial Results along with Limited Review Report by the Company's Statutory Auditor for the quarter ended 31st December, 2024 a Copy of which is enclosed herewith.

We wish to further inform you that the meeting of the board of directors commenced at 03:00 P.M. and concluded at 03:30 P.M.

Kindly take the same on your record and acknowledge receipt of the same.

Thanking You.

For and on behalf of
Brawn Biotech Limited

Priyanka Sharma
Digitally signed by
Priyanka Sharma
Date: 2025.02.12
15:33:37 +05'30'



Priyanka Sharma
Company Secretary and Compliance Officer

Membership No.: A50385
Encl: As above



BRAWN BIOTECH LTD.

CIN NO.: L74899DL1985PLC022468

Works : Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA
Email: distribution@brawnlabs.in | Website : www.brawngroup.in

Regd. Office : C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331
Email: solution@brawnbiotech.com

... for better life



C06C5

**BRAWN BIOTECH LTD.**


BRAWN BIOTECH LIMITED
 CIN:L74899DL1985PLC022468
 STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31st DECEMBER 2024
 REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024

Sr.	Particulars	Quarter ended			Nine Months ended		Rs in Lacs
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	Year Ended
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Revenue from operations						
a	Revenue from operations						
b	Other Income	384.48	329.68	284.28	1,120.57	1,304.82	1,649.47
	Total Revenue	0.08	0.13	0.38	0.21	0.42	8.81
2	Expenses	384.56	329.81	284.66	1,120.79	1,305.23	1,658.28
a	Cost of material consumed						
b	Purchase of stock-in-trade						
c	Change in inventories of finished goods, work in progress and stock in trade	800.26	245.20	283.82	1,320.05	1,069.65	1,558.90
d	Employee Benefit expenses	-454.49	31.69	-27.53	-321.20	78.18	-122.53
e	Depreciation and amortisation expenses	20.93	28.16	35.77	90.14	107.90	140.01
f	Finance Cost	3.08	2.71	2.71	8.33	7.17	9.94
g	Other expenses	0.01	0.15	0.01	0.16	0.16	0.38
	Total Expenses	57.95	56.27	50.62	154.67	162.42	225.99
		427.75	364.18	345.40	1,251.15	1,425.48	1,812.70
3	Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)						
4	Other Income	-43.18	-34.37	-60.74	-130.37	-120.24	-154.42
5	Profit from ordinary activities before exceptional items (3-4)						
6	Exceptional Items	-43.18	-34.37	-60.74	-130.37	-120.24	-154.42
7	Profit from ordinary activities before tax (5-6)						
8	Tax Expenses	-43.18	-34.37	-60.74	-130.37	-120.24	-154.42
9	Profit (Loss) for the period from continuing operations (7-8)						
10	Profit/(loss) from discontinuing operations	-43.18	-34.37	-60.74	-130.37	-120.24	-154.42
11	Tax expense of discontinuing operations						
12	Profit/(loss) from discontinuing operations (after tax) (10-11)						
13	Profit (Loss) for the period (9+12)						
14	Other Comprehensive Income	-43.18	-34.37	-60.74	-130.37	-120.24	-154.42
	Total Comprehensive Income	0.06	5.71	0.17	3.80	-0.42	0.28
15	Details of equity share capital	-43.12	-28.66	-60.57	-126.56	-120.66	-154.14
	Paid-up equity share capital	300.03	300.03	300.03	300.03	300.03	300.03
	Face value of equity share capital						
16	Reserve excluding Revaluation Reserve						
17	Earnings per share						
i	Basic earnings per share						
ii	Diluted earnings per share	-1.44	-0.96	-2.02	-4.22	-4.02	-5.14
		-1.44	-0.96	-2.02	-4.22	-4.02	-5.14

NOTES :-

- Results for the quarter ended on 31st December, 2024 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 12th February, 2025.
- The Statutory Auditors carried out the limited review for quarter ended 31st December, 2024. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone Un-audited Financial Results for the quarter ended on 31-12-2024 are available on company's website www.brawnbiotech.com and BSE website www.bseindia.com.
- Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
 For Brawn Biotech Limited


 Bej Raj Gupta
 Director
 DIN NO. 00924969
 Date: 12.02.2025
 Place: Delhi

**BRAWN BIOTECH LTD.****CIN NO.: L74899DL1985PLC022468**

Works : Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA
 Email: distribution@brawnbiotech.com | Website : www.brawngroup.in
Regd. Office : C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331
 Email: solution@brawnbiotech.com

...for better life



RAJIV UDAI & ASSOCIATES
CHARTERED ACCOUNTANTS

To,
The Board of Directors of
Brawn Biotech Limited


We have reviewed the accompanying statement of unaudited financial results of **Brawn Biotech Limited** for the period ended 31st December 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For Rajiv Udai & Associates
Chartered Accountants
Firm Registration No. 018764N


Rajeev Jain
Partner
Membership No. 099767
UDIN: 25099767BMIVB1951



Place: Delhi
Date: 12-02-2025